NRP2 and neoplasm: Administration of Nrp2-blocking antibodies in vivo inhibited tumor vascularity and growth in a mouse model of pancreatic neuroendocrine tumors, repressing F-acting-mediated motility via decreased SSH1-cofilin signaling [118].